In conclusion, our findings underscore the strong efficacy of conbercept in improving visual and anatomical outcomes among older diabetic macular edema patients, while also highlighting the pivotal role that baseline aqueous humor biomarker levels—particularly VEGF and IL-6—can play in identifying those most likely to benefit. This evidence concerns the gene VEGFA and diabetic macular edema.